News >

Expert Discusses Long-Term Dabrafenib/Trametinib Data in Melanoma

Angelica Welch
Published: Thursday, Aug 10, 2017

Georgina Long, MD

Georgina Long, MD
At the 2017 ASCO Annual Meeting, investigators reported 5-year follow-up data from a phase II study of dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with BRAF V600-mutant unresectable or metastatic melanoma.

OncLive: Could you provide an overview of this long-term follow-up?

Long: For the dabrafenib and trametinib phase I/II study, we are now reporting the 5-year PFS and OS. Overall, 13% of patients are progression-free at 5 years, which is pretty significant. When we turn to the OS, we know that about 28% of patients are still alive at 5 years. If we look at the subgroup that have less than 3 metastatic sites and a normal LDH at best line, the figures are even better. We have an OS of pretty significant—that is more than half of the patients with lower burden of disease and lower LDH alive at 5 years having been treated with dabrafenib/trametinib. These are actually the same subset of patients that do very well long term on immunotherapy, as well.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication